Consolidated Financial Highlights
| Millions of Yen | |||
|---|---|---|---|
| FY2020 | FY2021 | FY2022 | |
| Net sales | 102,995 | 110,179 | 103,261 |
| Operating income | 12,003 | 14,392 | 8,507 |
| Income before income taxes and minority interests |
11,900 | 14,591 | 9,044 |
| Income taxes | 3,312*1 | 4,022*2 | 2,395*3 |
| Net income | 8,587 | 10,569 | 6,649 |
| Total assets | 161,791 | 163,139 | 158,831 |
| R&D expenditures | 10,849 | 12,295 | 13,283 |
| Capital expenditures | 1,335 | 2,806 | 2,105 |
| Yen | |||
| Net income per share | 222.2 | 277.3 | 178.9 |
| Cash dividends per share | 90 | 90 | 80 |
- *1 As a result of tax effect accounting, corporate tax, resident tax and business tax (total \3,144 million), income taxes-deferred(\168 million)is included.
- *2 As a result of tax effect accounting, corporate tax, resident tax and business tax (total \3,215 million), income taxes-deferred(\807 million)is included.
- *3 As a result of tax effect accounting, corporate tax, resident tax and business tax (total \2,014 million), income taxes-deferred(\380 million)is included.
Sales of Main Products
| Billions of Yen | ||||
|---|---|---|---|---|
| Products | FY2020 | FY2021 | FY2022 | |
| Lialda® | Treatment of ulcerative colitis | 10.9 | 12.5 | 13.5 |
| Lexapro® | Antidepressant | 15.5 | 16.7 | 11.0 |
| Epadel | Drug for hyperlipidemia and arteriosclerosis obliterans | 10.1 | 8.7 | 7.1 |
| Goofice® | Treatment for chronic constipation | 4.9 | 6.0 | 6.9 |
| Movicol® | Treatment for chronic constipation | 3.5 | 4.9 | 5.4 |
| Tramcet® | Analgesic for chronic pain and pain after tooth extraction | 4.2 | 3.4 | 2.9 |
| Atelec® | Calcium channel blocker with a long-acting hypotensive effect | 3.9 | 3.4 | 2.6 | Urece | Gout and hyperuricemia | 0.2 | 0.9 | 2.2 |
| Dinagest | Therapeutic agent for endometriosis, adenomyosis and dysmenorrhea | 2.2 | 3.3 | 1.8 |
| Treprost® | Treatment for pulmonary arterial hypertension | 1.6 | 1.6 | 1.6 |
| Heparin Sodium MOCHIDA | Anticoagulant agent | 1.3 | 1.3 | 1.2 |
| Beselna | Therapeutic agent for condyloma acuminatum and actinic keratosis | 1.0 | 1.0 | 1.1 |
| Generic drugs | 25.6 | 26.7 | 29.5 | |
| Skin Care Products | 5.7 | 5.7 | 5.9 | |